Novabridge Biosciences ADR
(NBP)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 0 | 0 | 0 | 315 | 159 |
| Gross Profit | N/A | N/A | N/A | 315 | 159 |
| Operating Expenses | 17,140 | 8,503 | 0 | 10,949 | 12,209 |
| Operating Income | -17,140 | -8,503 | N/A | -10,634 | -12,050 |
| Other Income | 8,198 | -916 | 0 | 2,413 | -15,508 |
| Pre-tax Income | -8,942 | -9,419 | 0 | -8,221 | -27,558 |
| Net Income Continuous | -8,942 | -9,419 | N/A | -8,221 | -27,558 |
| Net Income Discontinuous | 34,364 | -6,898 | N/A | -25,035 | -33,908 |
| Net Income | $25,422 | $-16,317 | $N/A | $-33,256 | $-61,466 |
| EPS Basic Total Ops | 0.31 | -0.21 | N/A | -0.39 | -0.74 |
| EPS Basic Continuous Ops | -0.11 | -0.12 | N/A | -0.10 | -0.33 |
| EPS Basic Discontinuous Ops | 0.42 | -0.09 | N/A | -0.30 | -0.41 |
| EPS Diluted Total Ops | 0.31 | -0.21 | N/A | -0.39 | -0.74 |
| EPS Diluted Continuous Ops | -0.11 | -0.12 | N/A | -0.10 | -0.33 |
| EPS Diluted Discontinuous Ops | 0.42 | -0.09 | N/A | -0.30 | -0.41 |
| EPS Diluted Before Non-Recurring Items | -0.07 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-16,571 | $-8,503 | $N/A | $-10,634 | $-12,050 |